Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.

Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.

Blue Venture Fund returned as part of the latest funding to be raised by the mobile substance abuse treatment service.

The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.

Mayo Clinic had invested in and partnered the medical data software provider before joining a series C round also featuring NTTVC.

The European Commission-backed venture fund has secured commitments from Nestlé, Volkswohl Bund Versicherungen and Neste for its second close.

Novartis Venture Fund is among the participants in a series A round disclosed by the exosite drug developer at its public launch.

The WuXi AppTec-backed cancer drug developer has now raised $70m in total as it prepares to bring its lead candidate into the clinic.

Tufts Health Plan, DaVita Venture Group, Wanxiang America and Salesforce Ventures helped the multicultural patient engagement platform reach $24m in overall funding.

Fudan University’s Furong Investment has co-led a round for Singlera Genomics, which will use the cash to advance its pipeline of cancer screening products.